Cargando…

Chimeric antigen receptor T-cell therapy yields similar outcomes in patients with and without cytokine release syndrome

Chimeric antigen receptor (CAR) T-cell therapy has revolutionized the treatment of many patients with aggressive relapsed or refractory large B-cell lymphoma (LBCL). Treatment can be complicated by clinically evident cytokine release syndrome (CRS), which is characterized by the development of fever...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bhaskar, Shakthi T., Patel, Vivek G., Porter, David L., Schuster, Stephen J., Nastoupil, Loretta J., Perales, Miguel-Angel, Tomas, Ana Alarcon, Bishop, Michael R., McGuirk, Joseph P., Maziarz, Richard T., Chen, Andy I., Bachanova, Veronika, Maakaron, Joseph E., Riedell, Peter A., Oluwole, Olalekan O.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The American Society of Hematology 2022
Materias:	Lymphoid Neoplasia
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10468356/ https://www.ncbi.nlm.nih.gov/pubmed/36508286 http://dx.doi.org/10.1182/bloodadvances.2022008937

Ejemplares similares

Chimeric Antigen Receptor T Cell Therapy During the COVID-19 Pandemic
por: Bachanova, Veronika, et al.
Publicado: (2020)

Efficacy of checkpoint inhibition after CAR-T failure in aggressive B-cell lymphomas: outcomes from 15 US institutions
por: Major, Ajay, et al.
Publicado: (2023)

Low toxicity and excellent outcomes in patients with DLBCL without residual lymphoma at the time of CD19 CAR T-cell therapy
por: Wudhikarn, Kitsada, et al.
Publicado: (2022)

Cost-effectiveness of chimeric antigen receptor T-cell therapy in adults with relapsed or refractory follicular lymphoma
por: Potnis, Kunal C., et al.
Publicado: (2022)

Identifying an optimal fludarabine exposure for improved outcomes after axi-cel therapy for aggressive B-cell non-Hodgkin lymphoma
por: Scordo, Michael, et al.
Publicado: (2023)

Low incidence of invasive fungal disease following CD19 chimeric antigen receptor T-cell therapy for non-Hodgkin lymphoma
por: Little, Jessica S., et al.
Publicado: (2022)

SIRPα(+) macrophages are increased in patients with FL who progress or relapse after frontline lenalidomide and rituximab
por: Marques-Piubelli, Mario L., et al.
Publicado: (2022)

Risk assessment with low-pass whole-genome sequencing of cell-free DNA before CD19 CAR T-cell therapy for large B-cell lymphoma
por: Cherng, Hua-Jay J., et al.
Publicado: (2022)

A phase 1/2 study of lenalidomide and obinutuzumab with CHOP for newly diagnosed DLBCL
por: Cherng, Hua-Jay J., et al.
Publicado: (2022)

Early relapse identifies MCL patients with inferior survival after intensive or less intensive frontline therapy
por: Bond, David A., et al.
Publicado: (2021)

Comparison of 2-year outcomes with CAR T cells (ZUMA-1) vs salvage chemotherapy in refractory large B-cell lymphoma
por: Neelapu, Sattva S., et al.
Publicado: (2021)

Indirect comparison of tisagenlecleucel and historical treatments for relapsed/refractory diffuse large B-cell lymphoma
por: Maziarz, Richard T., et al.
Publicado: (2022)

A multicenter analysis of the outcomes with venetoclax in patients with relapsed mantle cell lymphoma
por: Sawalha, Yazeed, et al.
Publicado: (2023)

Impact of CD19 CAR T-cell product type on outcomes in relapsed or refractory aggressive B-NHL
por: Gauthier, Jordan, et al.
Publicado: (2022)

Haploidentical vs sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia
por: Wieduwilt, Matthew J., et al.
Publicado: (2022)

Decreased IL-10 accelerates B-cell leukemia/lymphoma in a mouse model of pediatric lymphoid leukemia
por: Fitch, Briana A., et al.
Publicado: (2022)

SBNO2 is a critical mediator of STAT3-driven hematological malignancies
por: Brandstoetter, Tania, et al.
Publicado: (2023)

Uptake of long-chain fatty acids from the bone marrow suppresses CD8(+) T-cell metabolism and function in multiple myeloma
por: Gudgeon, Nancy, et al.
Publicado: (2023)

Venetoclax sensitivity in multiple myeloma is associated with B-cell gene expression
por: Gupta, Vikas A., et al.
Publicado: (2021)

Spatiotemporal assessment of immunogenomic heterogeneity in multiple myeloma
por: Merz, Maximilian, et al.
Publicado: (2022)

Genetic subdivisions of follicular lymphoma defined by distinct coding and noncoding mutation patterns
por: Dreval, Kostiantyn, et al.
Publicado: (2023)

Autologous stem cell transplantation for large B-cell lymphoma with secondary central nervous system involvement
por: Akin, Serkan, et al.
Publicado: (2022)

High-sensitivity next-generation sequencing MRD assessment in ALL identifies patients at very low risk of relapse
por: Short, Nicholas J., et al.
Publicado: (2022)

Brentuximab vedotin plus AVD for Hodgkin lymphoma: incidence and management of peripheral neuropathy in a multisite cohort
por: Bowers, Jackson T., et al.
Publicado: (2023)

Inhibition of MYC translation through targeting of the newly identified PHB-eIF4F complex as a therapeutic strategy in CLL
por: Largeot, Anne, et al.
Publicado: (2023)

SNP rs6457327 in the HLA region on chromosome 6p is predictive of the transformation of follicular lymphoma
por: Wrench, David, et al.
Publicado: (2011)

Poor neutralizing antibody responses in 106 patients with WM after vaccination against SARS-CoV-2: a prospective study
por: Gavriatopoulou, Maria, et al.
Publicado: (2021)

Overexpression of wild-type IL-7Rα promotes T-cell acute lymphoblastic leukemia/lymphoma
por: Silva, Ana, et al.
Publicado: (2021)

Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma
por: Facon, Thierry, et al.
Publicado: (2021)

COVID-19 in patients with CLL: how can we change the odds?
por: Herishanu, Yair, et al.
Publicado: (2021)

The microenvironment of DLBCL is characterized by noncanonical macrophages recruited by tumor-derived CCL5
por: Manfroi, Benoît, et al.
Publicado: (2021)

Nras(Q61R/+) and Kras(−/−) cooperate to downregulate Rasgrp1 and promote lympho-myeloid leukemia in early T-cell precursors
por: Wen, Zhi, et al.
Publicado: (2021)

Toward prevention of childhood ALL by early-life immune training
por: Hauer, Julia, et al.
Publicado: (2021)

Activated natural killer cells predict poor clinical prognosis in high-risk B- and T-cell acute lymphoblastic leukemia
por: Duault, Caroline, et al.
Publicado: (2021)

Association of allele-specific methylation of the ASNS gene with asparaginase sensitivity and prognosis in T-ALL
por: Akahane, Koshi, et al.
Publicado: (2022)

Asparaginase enzyme activity levels and toxicity in childhood acute lymphoblastic leukemia: a NOPHO ALL2008 study
por: Lynggaard, Line Stensig, et al.
Publicado: (2022)

Determination of MYD88(L265P) mutation fraction in IgM monoclonal gammopathies
por: Bagratuni, Tina, et al.
Publicado: (2022)

Circulating tumor DNA for comprehensive noninvasive monitoring of lymphoma treated with ibrutinib plus nivolumab
por: Bruscaggin, Alessio, et al.
Publicado: (2021)

A simplified frailty score predicts survival and can aid treatment-intensity decisions in older patients with DLBCL
por: Isaksen, Kathrine T., et al.
Publicado: (2021)

CXCR4 PET/MRI for follow-up of gastric mucosa–associated lymphoid tissue lymphoma after first-line Helicobacter pylori eradication
por: Mayerhoefer, Marius E., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_646e48j341t2rcp2fra8sus56b